BioCentury
ARTICLE | Distillery Therapeutics

Cancer

July 17, 2018 5:33 PM UTC

Mouse studies suggest vaccines based on R123H-mutant IDH1 could help treat sarcomas harboring the mutation. In a syngeneic mouse model of sarcoma expressing the IDH1 R132H mutation, vaccination with a R132H-mutant IDH1 peptide decreased tumor growth compared with vaccination with wild-type IDH1 peptide or vehicle. Next steps could include testing the mutant peptide in models of other cancers harboring the R123H IDH1 mutation.

Bayer AG has BAY 1436032, a pan-mutant IDH1 inhibitor, in Phase I testing for acute myelogenous leukemia (AML) and solid tumors...